1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • August 2016
  • 411 pages
  • GlobalData
Report ID: 2913199

Summary

Table of Contents

Search Inside

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

Summary
Various therapeutic options are available to treat patients with atrial fibrillation (AF), and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially, an antiarrhythmic drug for rhythm control. All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important role in stroke prevention in AF. However, since 2010, and the launch of the first of the new oral anticoagulants (NOACs), a shift in the treatment of patients with AF has occurred. The NOACs offer a significant advancement in anticoagulation and their continued uptake will be the main driver of growth in the AF market over the next 10 years.

It is estimated that 2015 sales for AF at approximately $8.0 Billion across the 8MM. The US dominates the overall size of the AF market, generating an estimated $5.7 Billion in 2015 and accounting for 70.6% of the overall size of the market. This is mainly due to the large prevalent AF population in the US, early adoption of the new oral anticoagulants (NOACs), and higher prices for AF medications in this market.

As per Jesus Cuaron, Analyst: “Since the launch of the first NOACs in 2010, this drug class has experienced substantial uptake, accounting for $6.8 billion, approximately 85% of all atrial fibrillation sales revenue across the 8MM in 2015. This uptake will continue to increase, and will be the main driver of growth in the atrial fibrillation space through 2022.

Major drivers for the growth of the AF market over the forecast period will include -
- The continued uptake of the NOACs for the prevention of stroke in patients with AF. Due to the advances that the NOACs provide in terms of improved safety and the lack of a need for routine monitoring, NOAC uptake will continue to increase, taking market share away from the vitamin K antagonists, such as warfarin.
- A shift in AF treatment guidelines to using the CHA2DS2-VASc score instead of the CHADS2 score for assessing stroke risk, which will cause a larger proportion of lower-risk patients to receive anticoagulant treatment.
- The approval and launch of the first reversal agents for the NOACs, which will alleviate physician and patient concerns regarding a lack of a reversal agent in the event of uncontrolled bleeding, thereby increasing overall uptake.

Companies attempting to penetrate the AF market and differentiate their products, particularly those companies that market NOACs, are doing so with two main strategies: label expansion to increase physician brand familiarity, and intensive marketing to disseminate clinical trial results. Gaining approval for additional cardiovascular indications has been a strategy that has worked very well for Bayer and Janssen, the two companies that jointly developed and market Xarelto

The report “PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025” provides overview of AF, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Specially, this report provides the following analysis -
- Annualized AF therapeutics market revenue, annual cost of therapy, and treatment usage pattern data from 2015, forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the AF therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global AF therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: ARCA Biopharma, Armetheon Inc., Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardiome Pharma, Daiichi-Sankyo, Janssen Pharmaceuticals, Isis Pharmaceuticals, Laboratoires Pierre Fabre, Otsuka Pharmaceutical, Pfizer, Portola Pharmaceuticals, Sanofi, Servier, Xention

Highlights
Key Questions Answered
- The anticoagulant market for stroke prevention in AF has become increasingly crowded. How will the drug treatment landscape for AF change? Which of the NOACs will become the market leader over the next ten years? What are the key drivers and barriers to this change?
- The AF market is marked by the presence of a number of unmet needs. What are the main unmet needs in the treatment of AF? Will the drugs under development fulfil the unmet needs of the AF market?
- Will any late-stage anticoagulants drugs make a significant impact on the AF market? What subgroups of the AF population will they target?

Scope
- Overview of AF, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized AF therapeutics market revenue, annual cost of therapy, and treatment usage pattern data from 2015, forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the AF therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global AF therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global AF therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AF therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global AF therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Prescription Drugs Markets in China

  • $ 4000
  • Industry report
  • April 2017
  • by Asia Market Information & Development Company

China’s demand for Prescription Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...

Hypertension Drugs Markets in China

  • $ 4000
  • Industry report
  • May 2017
  • by Asia Market Information & Development Company

China’s demand for Hypertension Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...

Global Acute Ischemic Stroke Therapeutics Market 2017-2021

  • $ 3500
  • Industry report
  • August 2017
  • by Infiniti Research Limited

About Acute Ischemic Stroke Therapeutics AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.